The New Economics of Launch
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
The New Economics of Launch
-
ナレーター：
-
著者：
In this episode of Bench to Boardroom, we examine why maximizing value across a life sciences portfolio increasingly requires an asset-specific, geography-agnostic approach rather than relying on the traditional “U.S. first, Europe second, rest of world later” launch model. Through examples in oncology/hematology, cell and gene therapy, and immunology, the discussion explores how launch sequencing, emerging regulatory pathways, evidence generation, market access strategy, and international pricing dynamics can materially influence net present value (NPV), time to patient access, and long-term commercial success. The episode argues that the most valuable portfolios of the future will be built not by following convention, but by strategically matching each asset with the launch sequence that optimizes both enterprise value and patient impact.